药品审评中心药物临床试验期间安全信息评估与风险管理工作程序（试行）

Chapter I General Provisions

Article 1: To standardize the clinical

Safety information assessment and risk management during clinical trials, in accordance with the Drug Administration Law,

"Regulations on Drug Registration Management", "Safety Information Evaluation and Management during Drug Clinical Trials"

This work procedure is formulated in accordance with the provisions of the "Regulations (Trial)" (Notice No. 5 of 2020) and other regulations.

Article 2 During the clinical trial, the sponsor shall be responsible for the management of the safety risks of the drug clinical trial.

The main responsibility of the management is to carry out risk monitoring, identification, assessment and control, and promptly report to the drug review center

Report suspected and unexpected serious adverse reactions (SUSAR) and other potentially serious safety

The sponsor shall submit the development safety update report (DSUR) regularly.

If safety issues or other risks are found, risk control measures should be taken in a timely manner, including

including general risk management measures (such as adjusting clinical trial protocols, etc.), voluntary suspension or termination

Stop clinical trials and report to the Center for Drug Evaluation.

The Center for Drug Evaluation will review the safety report (information) and risk management information submitted by the applicant.

In combination with the original review and approval of drug clinical trials, clinical trial risk monitoring and

If the risk management measures implemented by the sponsor are not adequate, further

Risk control requirements, such as risk management notification, general risk management measures, suspension orders

Clinical trials and termination of clinical trials, etc.

Chapter II Responsibilities and Division of Labor

Article 3 The Clinical Trial Management Office shall assess safety information and risks during the clinical trial.

The following main duties are performed in risk management:

Responsible for receiving SUSAR case reports and other potentially serious safety

Sexual risk information, DSUR, other sources of relevant safety reports/information (registration platform

Suspicious risk information, emergency prevention and treatment drugs, etc.);

Responsible for the normative review and risk assessment of all safety reports (information);

Responsible for organizing and coordinating relevant review departments to conduct professional review of safety reports (information)

Review and risk assessment and control; responsible for summarizing the risk control opinions put forward by various disciplines

Combined notification to sponsors;

Responsible for following up the sponsor's response to safety risk inquiries during clinical trials; Responsible for coordinating

with the sponsor on matters related to safety risk management during clinical trials.

Risk communication.

Article 4 Safety Information Assessment and Risk Management by the Review Department during Clinical Trials

The main duties at work are:

The clinical trial management department found that the risk level was relatively high during the risk monitoring and handling process.

High and difficult problems that are difficult to handle require the initiation of clinical, pharmacological, toxicological, statistical and clinical

During the pharmacology, pharmacy and other professional reviews, the review department is responsible for the applicant's

Further professional review and risk assessment and control of safety reports (information) submitted during the inspection

If necessary, the departmental technical committee will be convened to put forward risk control opinions.

Chapter III Working Procedures for Safety Information Monitoring, Assessment and Risk Management

Article 5 The Drug Evaluation Center adopts the internal clinical trial safety risk management system

(hereinafter referred to as risk management system) to carry out safety information monitoring, assessment and risk management

SUSAR reports, DSUR reports, and other potentially serious safety information can be

The clinical trial management department will conduct regulatory review and risk management.

risk assessment, and if necessary, initiate the review department to conduct professional review and risk assessment, and achieve

Inquiry-style communication by the sponsor. The workflow diagram of the risk management system is shown in Appendix 1.

Article 6 The Clinical Trial Management Office shall review the safety report in accordance with relevant laws and regulations.

Conduct a regulatory review. If it does not meet the requirements, it will be returned to the applicant for improvement.

The Clinical Trial Management Office organizes task initiation and risk assessment in the risk management system.

For those who clearly recommend taking risk control measures (such as sending a notification letter or

Notice), marked as key concerns, and the rest marked as general concerns, based on the risk situation and

The review departments jointly evaluate and reach a conclusion on the handling.

There are five types of processing conclusions: archiving, risk management notification, general risk management, temporary

Suspension of clinical trials and termination of clinical trials. (1) Archiving: After evaluation, it is considered that the current

When there are monitoring measures and no further risk control suggestions, it can be clarified as: No treatment suggestions for the time being

Archive and save, and end the task. (2) Risk management notification: After the assessment, it is considered necessary to conduct safety

Risk warning: Risk monitoring measures may need to be strengthened, but no further measures are mandatory.

When the risk control measures are implemented, the applicant can be informed of the safety risk management.

No response is required. (3) General risk management: After evaluation, it is considered that clinical trials have certain safety risks.

The safety risk requires the sponsor to take further risk control measures, such as modifying the clinical trial

The trial protocol, investigator's manual, informed consent form, or the safety update report during the research and development period should be adjusted.

(4) Suspension of clinical trials: After evaluation, it is found that the clinical trials have great risks.

If the subject continues to participate in the trial, the risk may outweigh the benefit, so a temporary

(5) Termination of clinical trials: After evaluation, it is determined that the clinical trials have significant

Safety risk: if it is confirmed that the risk to the subject of the trial outweighs the benefit, termination may be adopted

Clinical trials.

If the risk control opinion is general risk management or suspension/termination of clinical trials,

Submit to the center leader for review.

Article 7 After risk identification and assessment, the Clinical Trial Management Office may

If there is a concern, the relevant review department should be initiated for review.

Submit it to the Clinical Trial Management Office to form the final risk management opinion.

During the review process, experts' opinions may be sought as needed.

Refer to the "Working Rules of the Expert Consultation Meeting of the Drug Review Center (Trial)" for implementation.

The safety risk issues of key focus situations shall be managed by the Clinical Trial Management Office and the Review

The departments shall determine through consultation and communicate and update regularly.

Article 8 After the final risk handling opinion is formed,

For notification, general risk management, suspension/termination of clinical trials, the Clinical Trial Management Office shall

Standardize the format of the "Clinical Trial Risk Management Notification Letter" / "Clinical Trial Risk Management Notification Letter"

Control Notice / Suspension of Clinical Trial Notice / Termination of Clinical Trial Notice

(See attachments 3/4/5/6 for details) and sent to the applicant through the applicant's window.

Stamped with the National Drug Administration's special drug registration seal (electronic signature).

After the "Notice of Suspension of Clinical Trial"/"Notice of Termination of Clinical Trial" is sent,

According to the "Regulations on Registration and Information Disclosure of Drug Clinical Trials (Trial)", clinical trials

The Administration Office will publish the trial status information on the Drug Clinical Trial Registration and Information Disclosure Platform.

Updated to "order to suspense/order to terminate".

Article 9 After the Center for Drug Evaluation issues the "Clinical Trial Risk Control Notice", the applicant

The clinical trial management department is in the risk management system.

The review department can further review and evaluate the feedback in the system. If necessary, the review department can restart the review process.

Feedback is subject to professional review, risk assessment and control.

If the sponsor needs to restart the clinical trial after being ordered to suspend the trial, it should follow the supplementary

According to the technical review conclusion of the supplementary application, the Business Management Office will

"Notice of resumption of clinical trials" (see Appendix 7 for details) or "Notice of continued suspension of clinical trials"

The Notice (see Appendix 8 for details) is sent to the applicant through the applicant's window.

Chapter 4 Risk Communication

Article 10 Safety Information Monitoring, Evaluation and Risk Management Process during Clinical Trials

In the risk management system, the Drug Evaluation Center can use the “R&D

During the period, the applicant can communicate with the applicant through the "Safety Risk Inquiry" and the applicant can communicate with the applicant through the "Applicant Window-

Safety risk management during clinical trials - safety risk communication and feedback during R&D"

Review and provide feedback. You can also communicate with the sponsor by phone, email, etc.

In this case, after the formal issuance of the "Clinical Trial Risk Control Notice" and "Clinical Trial Suspension Notice",

Before submitting the Notice of Termination of Clinical Trial, the Clinical Trial Management Office shall

Communicate with the sponsor. However, when the subjects are at serious risk,

When the applicant is notified immediately, the Center may directly order the suspension or termination of the program upon approval.

Stop clinical trials to control risks in a timely manner and protect the safety of subjects.

According to work needs, the Clinical Trial Management Office may propose to

The Center held a risk communication meeting with the Department of Clinical Trials (participants in the clinical trial).

It is held in the form of a "chief review collegial meeting" and external meetings are held in accordance with the central review communication management

According to work needs, the Drug Evaluation Center may also cooperate with relevant clinical trial institutions to

Conduct risk communication with the relevant regulatory agency/ethics committee.

Sponsors may follow the relevant provisions of the “Administrative Measures for Communication and Exchange of Drug Development and Technical Review”.

Regulations stipulate that communication and exchanges on major safety issues in clinical trials shall be made through the center website.

The Clinical Trial Management Office should participate in the communication and exchange of clinical trial safety risks.

meeting.

Chapter 5 Others

Article 11 Safety reports (information) during clinical trials must be evaluated and

Identify safety signals. For safety risks found, risk control opinions should be put forward within a time limit.

The specific working time limit is shown in Appendix 2.

The review is timed according to the new task.

For tasks that have not been processed beyond the time limit, no opinion is given and the process ends.

Relevant process information can be queried in the file task.

Article 12 This work procedure shall be implemented from the date of publication.

Procedures for Safety Information Assessment and Risk Management during Drug Clinical Trials at the Center for Drug Evaluation

(Trial)" (Pharmaceutical Review Industry [2021] No. 5) is hereby repealed at the same time.

Annex 1

药审中心临床试验期间安全风险管理系统流程图



Note 1: In cases of key concern, the Clinical Trial Management Office should activate the relevant review departments.

Note 2: Risk control opinions for general risk management or suspension/termination of clinical trials should be submitted to the center leadership for review.

Annex 2

安全性报告（信息）在风险管理系统中的工作时限

Safety Information Clinical Trial		Inspection Management Department	Review department	center lead	send Notice/ Notification letter	Total work time limit
WHISPERING		16	10	2	2	30
Other potentially serious Security risk information breath		16	10	2	2	30
DSUR		25	140	10	5	180
Others source	Registration platform	8	5	1	1	15
	Emergency Prevention drug	8	5	1	1	15

Note: The above time limits are all working days.

Annex 3

Notice from the Center for Drug Evaluation of the State Drug Administration on the Risk Management of Clinical Trials of XX (Drug Name)

(Sponsor):

According to the XX information reported by your company, after review, please ask the sponsor to

Pay attention to the following risks:

National Drug Administration Drug Evaluation Center

XXXX Year XX Month XX Day

Annex 4

Notice No.:

State Drug Administration

Clinical Trial Risk Control Notice

(Sponsor):

According to Article 1 of the Drug Administration Law of the People's Republic of China,

Check, (drug name) approved/implicitly licensed on XXXX (acceptance number:

XXX, notification number: XXX) clinical trial, there are currently certain safety risks

It is necessary to strengthen and improve the safety information assessment and risk management of clinical trials to protect the subjects.

Safety of the people.

(1. Clarify the specific problems that exist; 2. Clarify the relevant requirements for risk control).

The sponsor should take relevant measures in a timely manner and approve the drug within 20 working days.

The review center website responds to the completion or progress of relevant measures (scan

Please stamp the reply document with your company's seal.

Special seal for drug registration issued by the State Drug Administration

(Electronic Signature)

XXXX Year X Month XX Day

Annex 5

Notice No.:

State Drug Administration

Notice of suspension of clinical trials

(Sponsor):

According to Article 1 of the Drug Administration Law of the People's Republic of China,

Check, (drug name) approved/implicitly licensed on XXXX (acceptance number:

XXX, Notification No.: XXX) Clinical trial, currently there are great safety risks

If there is a risk, the clinical trial should be suspended immediately. (Specify the specific requirements for partial suspension/full suspension

beg).

(Please specify the reasons for suspension or risk points).

Sponsors should comprehensively strengthen and improve risk control measures in response to the above situations to ensure

Protect the safety of clinical trial subjects.

After the applicant completes the relevant work, he or she may submit a written request to the Center for Drug Evaluation to resume clinical trials.

The information required for the supplementary application for resumption of clinical trials should include:

Notice of Suspension of Clinical Trials, response to reasons for suspension of clinical trials, and measures to be taken

risk control measures and related technical information.

Special seal for drug registration issued by the State Drug Administration

(Electronic Signature)

XXXX Year X Month XX Day

Annex 6

Notice No.:

State Drug Administration

Notice of Termination of Clinical Trial

(Sponsor):

According to Article 1 of the Drug Administration Law of the People's Republic of China, after review, (Drug name) approved/implicitly licensed on XXXX XXXX (Acceptance No.: XXX, Notice No.: XXX) Clinical trial currently has significant safety risks and should be stopped immediately. The clinical trial will be terminated immediately.

The subjects stop using the study drug, no new subjects shall be included, and all trial drugs shall be Recycling is required.

(Please specify the reasons for termination or risk points).

If the sponsor needs to re-conduct the relevant clinical trial, it should do so after completing the relevant work. Submit the application as a new clinical trial application.

Special seal for drug registration issued by the State Drug Administration

(Electronic Signature)

XXXX Year X Month XX Day

Annex 7

Notice No.:

State Drug Administration

Notice of resumption of clinical trials

(Sponsor):

According to the Drug Administration Law of the People's Republic of China and relevant regulations, after review, XXXX (Drug name) received on XX/XX/XX (Acceptance No.: XXX, Notice No.: XXX)

The application for resumption of suspended clinical trials and the relevant materials meet the relevant requirements and are approved to resume clinical trials.

Bed test.

(Matters that applicants need to be reminded of).

For other matters, please follow the requirements of the original clinical trial notice.

Special seal for drug registration issued by the State Drug Administration

(Electronic Signature)

XXXX Year X Month XX Day

Annex 8

Notice No.:

State Drug Administration

Notice of continued suspension of clinical trials

(Sponsor):

According to Article 1 of the Drug Administration Law of the People's Republic of China, after review,

(Drug name) received on XXXX (Acceptance No.: XXX, Notice No.:

XXX) The application for resumption of the suspended clinical trial and the related materials do not meet the relevant requirements.

The clinical trial is suspended for the following reasons:

(Specific reasons for continuing to suspend clinical trials).

Special seal for drug registration issued by the State Drug Administration

(Electronic Signature)

XXXX Year X Month XX Day